Does age, gender, or the presence of vascular dementia influence the safety or effectiveness Alzheimers drugs?
Overall the level of evidence is poor. Indirect comparisons suggest that age, gender, or ethnicity does not influence the safety and efficacy of donepezil. Limited evidence suggests that patients older than 75 years may derive greater benefit from rivastigmine. In patients who have Alzheimer’s disease and vascular dementia, the following drugs have been shown to provide benefit: donepezil, galantamine, rivastigmine, and memantine.
